Peking University Cancer Hospital & Institute
Clinical trials sponsored by Peking University Cancer Hospital & Institute, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a simple scan replace biopsies for cancer immunotherapy? Results expected Dec 2026 (estimated)
- Targeted PET scan spots cancer protein, guiding treatment Results expected Dec 2026 (estimated)
- New PET scan could predict breast cancer drug success before treatment Results expected Dec 2026 (estimated)
- New imaging agent could sharpen bladder cancer detection Results expected Dec 2026 (estimated)
- Why does esophageal cancer come back after treatment? researchers search medical records for clues Results expected Dec 2026 (estimated)
-
New drug cocktail targets rare, aggressive melanoma
Disease control By invitation onlyThis phase 1 trial tests two experimental drug combinations—AK104 or AK112 plus axitinib—in people with metastatic mucosal melanoma, a rare and hard-to-treat skin cancer. The study aims to find a safe dose and see whether the combinations shrink tumors. Participants receive the d…
Phase 1 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
AI biomarker may reveal who responds to esophageal cancer immunotherapy
Diagnosis OngoingThis trial tests whether a new AI-driven biomarker, called the Microbial-Sensory Coupling (MSC) index, can predict how well patients with esophageal squamous cell carcinoma respond to anti-PD-1 immunotherapy. The biomarker measures the spatial relationship between a specific bact…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Aug 06, 2026 00:00 UTC